Canadian drug discovery technology company AbCellera, which analyses and identifies antibodies for pharmaceutical companies working on a coronavirus treatment and other medicines, has said that it raised $105 million in funds.

AbCellera has been working with pharmaceutical firm Eli Lilly and Co which is developing a coronavirus drug based on antibodies from patients that have recovered from the disease.

AbCellera uses computer vision and machine learning to quickly analyse data from human samples, and pharmaceutical clients then use that to develop drugs, AbCellera Chief Executive Carl Hansen said.

Read the full Reuters story here.